Back to Search
Start Over
Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia.
- Source :
-
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2022 Mar; Vol. 39 (2), pp. 187-192. Date of Electronic Publication: 2021 Aug 09. - Publication Year :
- 2022
-
Abstract
- A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.
- Subjects :
- Bortezomib adverse effects
Child
Humans
Immunoglobulins, Intravenous therapeutic use
Magnetic Resonance Imaging
Male
Guillain-Barre Syndrome chemically induced
Guillain-Barre Syndrome diagnosis
Guillain-Barre Syndrome drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1521-0669
- Volume :
- 39
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Pediatric hematology and oncology
- Publication Type :
- Report
- Accession number :
- 34369835
- Full Text :
- https://doi.org/10.1080/08880018.2021.1959691